Every Form 4 that LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LFMDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFMDP filings page.
LifeMD, Inc. (symbol: LFMD) is the issuer of record for a Form 4 filing submitted to the SEC.
LifeMD, Inc. (LFMD) director John R. Strawn Jr. reported two equity compensation grants of the company’s Common Stock. On May 4, 2026, he acquired 50,000 restricted shares that, per a footnote, vest immediately. On August 11, 2026, he received an additional 35,000 restricted shares that vest on June 1, 2027. Both awards were granted at a reported price of $0.00 per share, consistent with stock-based compensation rather than open-market purchases. A separate holding entry shows 60,000 shares of Common Stock held indirectly through Strawn Pickens LLP.
LifeMD, Inc. director Joseph DiTrolio reported an acquisition of 35,000 shares of common stock as a grant/award, with no cash price per share. These are restricted shares that vest on June 1, 2027. Following this grant, DiTrolio directly holds 308,413 shares of LifeMD common stock.
Simon Roberto reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. director Roberto Simon reported three equity compensation awards of common stock on December 2, 2024. These were grants of restricted shares totaling 50,000; 6,162; and 24,648 shares at a stated price of $0.0000 per share. One grant vests on December 2, 2024, one vests immediately, and one vests on June 1, 2025.
Simon Roberto reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that director Simon Roberto received two equity awards of common stock. On May 4, 2026, he was granted 50,000 restricted shares that vested immediately. On August 11, 2026, he received 35,000 restricted stock units that are scheduled to vest on June 1, 2027.
LifeMD, Inc. director Calum Archibald MacRae reported a grant of 35,000 shares of common stock as an equity award. The restricted shares were acquired at $0.00 per share and are scheduled to vest on June 1, 2027. Following this award, MacRae directly holds 73,865 shares of LifeMD common stock.
LifeMD, Inc. reported that Chief Technology Officer Sripad Umesh received an award of 75,000 shares of Common Stock as a grant or other acquisition. The award carries a zero dollar price per share, indicating it is compensation rather than an open-market purchase.
According to the footnote, this grant consists of restricted stock units that vest over time: 25,000 units on June 1, 2027, another 25,000 units on June 1, 2028, and the remaining units on June 1, 2029. Following this award, Umesh holds 75,000 shares directly, reflecting a new equity position that vests in stages over three years.
Kavthekar Atul reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that its Chief Financial Officer, Atul Kavthekar, received a grant of 337,500 shares of Common Stock in the form of restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase.
Following this grant, Kavthekar directly holds 337,500 shares. The units vest over time: 112,500 shares on March 16, 2027, another 112,500 shares on March 16, 2028, and the remaining portion on March 16, 2029, aligning his compensation with multi‑year service.
Pisano Christopher A reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 shares of common stock in the form of restricted stock units on March 30, 2026. The award carries no purchase price.
According to the vesting terms, 50,000 units vest on the grant date, and an additional 50,000 units also vest on the grant dateMarch 30, 2027. A further 50,000 units vest on March 30, 2027, with the remaining units vesting on March 30, 2028, aligning the compensation with continued service at the company.